M M Shi1, S P Myrand, M R Bleavins, F A de la Iglesia. 1. Genomic Pathology Laboratory, Parke-Davis Pharmaceutical Research, Warner-Lambert Company, Ann Arbor, MI 48105, USA. michael.shi@wl.com
Abstract
AIMS: The two electron reduction of quinones to hydroquinones by NAD(P)H quinone oxidoreductase (NQO1) plays an important role in both activation and detoxification of quinone and similarly reactive compounds. A single nucleotide polymorphism at exon 6 leads to an amino acid change at codon 187 from proline to serine. The variant allele has been associated with decreased NQO1 enzyme activity and increased cancer risks. The aim of this study was to develop a rapid genotyping procedure for epidemiological and clinical research into the potential biological and toxicological implications associated with this genetic polymorphism. METHODS: A high throughput genotyping method using fluorogenic probes has been developed to screen this single nucleotide polymorphism. This assay utilises the 5' nuclease activity of Taq polymerase in conjunction with fluorogenic TaqMan probes. The TaqMan genotyping procedure was validated by a restriction fragment length polymorphism method and direct sequencing. RESULTS: This method can be used for the rapid screening of known polymorphisms in large populations. In a population of 143 unrelated individuals, Pro/Pro (wildtype), Pro/Ser (heterozygous), and Ser/Ser (mutant) genotypes were 69.2%, 26.6%, and 4.2%, respectively. CONCLUSIONS: This genotyping method is highly accurate and could be applied to automated large scale genotyping studies.
AIMS: The two electron reduction of quinones to hydroquinones by NAD(P)H quinone oxidoreductase (NQO1) plays an important role in both activation and detoxification of quinone and similarly reactive compounds. A single nucleotide polymorphism at exon 6 leads to an amino acid change at codon 187 from proline to serine. The variant allele has been associated with decreased NQO1 enzyme activity and increased cancer risks. The aim of this study was to develop a rapid genotyping procedure for epidemiological and clinical research into the potential biological and toxicological implications associated with this genetic polymorphism. METHODS: A high throughput genotyping method using fluorogenic probes has been developed to screen this single nucleotide polymorphism. This assay utilises the 5' nuclease activity of Taq polymerase in conjunction with fluorogenic TaqMan probes. The TaqMan genotyping procedure was validated by a restriction fragment length polymorphism method and direct sequencing. RESULTS: This method can be used for the rapid screening of known polymorphisms in large populations. In a population of 143 unrelated individuals, Pro/Pro (wildtype), Pro/Ser (heterozygous), and Ser/Ser (mutant) genotypes were 69.2%, 26.6%, and 4.2%, respectively. CONCLUSIONS: This genotyping method is highly accurate and could be applied to automated large scale genotyping studies.
Authors: R D Traver; T Horikoshi; K D Danenberg; T H Stadlbauer; P V Danenberg; D Ross; N W Gibson Journal: Cancer Res Date: 1992-02-15 Impact factor: 12.701
Authors: Inna Belfer; Tianxia Wu; Heather Hipp; Joan Walter; Michele Scully; Paul A Nyquist; Antonella Bollettino; David Goldman; Mitchell B Max; Thomas J DeGraba Journal: Int J Stroke Date: 2010-06 Impact factor: 5.266
Authors: J Li; G H Zhao; F Chen; H Q Song; X Q Zhu; G H Zhao; J Li; F Chen; R Q Lin; Y B Weng; M S Mahmoud; F C Zou Journal: Ann Trop Med Parasitol Date: 2011-10
Authors: Aryeh I Herman; Henry R Kranzler; Joseph F Cubells; Joel Gelernter; Jonathan Covault Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2006-07-05 Impact factor: 3.568
Authors: Xingguang Luo; Henry R Kranzler; Lingjun Zuo; Shuang Wang; Nicholas J Schork; Joel Gelernter Journal: Am J Hum Genet Date: 2006-04-11 Impact factor: 11.025
Authors: Chupong Ittiwut; Jennifer Listman; Apiwat Mutirangura; Robert Malison; Jonathan Covault; Henry R Kranzler; Atapol Sughondhabirom; Nuntika Thavichachart; Joel Gelernter Journal: Genomics Date: 2007-11-05 Impact factor: 5.736
Authors: Huiping Zhang; Henry R Kranzler; James Poling; Jeffrey R Gruen; Joel Gelernter Journal: Neuropsychopharmacology Date: 2009-07-15 Impact factor: 7.853